Thrombosis Journal (Oct 2023)

A retrospective multicenter cohort study of the association between anti-Factor Xa values and death, thromboembolism, and bleeding in patients with critical COVID-19

  • Sandra Jonmarker,
  • Jacob Litorell,
  • Felix Alarcon,
  • Kais Al-Abani,
  • Sofia Björkman,
  • Maria Farm,
  • Jonathan Grip,
  • Mårten Söderberg,
  • Jacob Hollenberg,
  • Rebecka Rubenson Wahlin,
  • Thomas Kander,
  • Liivi Rimling,
  • Johan Mårtensson,
  • Eva Joelsson-Alm,
  • Martin Dahlberg,
  • Maria Cronhjort

DOI
https://doi.org/10.1186/s12959-023-00541-z
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Patients with critical COVID-19 have a high risk of thromboembolism, but intensified thromboprophylaxis has not been proven beneficial. The activity of low-molecular-weight heparins can be monitored by measuring anti-Factor Xa. We aimed to study the association between anti-Factor Xa values and death, thromboembolism, and bleeding in patients with critical COVID-19. Method This retrospective cohort study included adult patients with critical COVID-19 admitted to an intensive care unit at three Swedish hospitals between March 2020 and May 2021 with at least one valid peak and/or trough anti-Factor Xa value. Within the peak and trough categories, patients’ minimum, median, and maximum values were determined. Logistic regressions with splines were used to assess associations. Results In total, 408 patients had at least one valid peak and/or trough anti-Factor Xa measurement, resulting in 153 patients with peak values and 300 patients with trough values. Lower peak values were associated with thromboembolism for patients’ minimum (p = 0.01), median (p = 0.005) and maximum (p = 0.001) values. No association was seen between peak values and death or bleeding. Higher trough values were associated with death for median (p = 0.03) and maximum (p = 0.002) values and with both bleeding (p = 0.01) and major bleeding (p = 0.02) for maximum values, but there were no associations with thromboembolism. Conclusions Measuring anti-Factor Xa activity may be relevant for administrating low-molecular-weight heparin to patients with critical COVID-19. Lower peak values were associated with an increased risk of thromboembolism, and higher trough values were associated with an increased risk of death and bleeding. Prospective studies are needed to confirm the results. Trial registration The study was retrospectively registered at Clinicaltrials.gov, NCT05256524, February 24, 2022.

Keywords